Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Phase II non-comparative multicenter trial Fagard C. 1, Descamps D. 2, Dubar V. 3, Colin C.1,Taburet AM. 4, Roquebert B. 2, Katlama C. 5, Jacomet C.

Published byDasia Kittredge Modified over 9 years ago

Similar presentations

Presentation on theme: "A Phase II non-comparative multicenter trial Fagard C. 1, Descamps D. 2, Dubar V. 3, Colin C.1,Taburet AM. 4, Roquebert B. 2, Katlama C. 5, Jacomet C."— Presentation transcript:

1 A Phase II non-comparative multicenter trial Fagard C. 1, Descamps D. 2, Dubar V. 3, Colin C.1,Taburet AM. 4, Roquebert B. 2, Katlama C. 5, Jacomet C. 6, Piketty C. 7, Molina JMM. 8, Chene G. 1, Yazdanpanah Y 3 and the ANRS 139 TRIO Trial Group Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial TUPDB204

2 ANRS 139 TRIO Trial – Cape Town 2009 2 Baseline characteristics (n = 103) HIV RNA log 10, copies/ml, median (IQR)4.0(3.6 – 4.6) CD4 cells/mm 3, median (IQR)255(132 – 350) CD4 Nadir in cells/mm 3, median (IQR) 79(25– 169) ART duration prior to enrollment yrs, median (IQR) 13(11 – 15) No. mutations at screening, median (IQR) Major PI4(3 – 5) NRTIs5(4 – 6) NNRTIs1(0 – 2) OBT received with RAL/ETR/DRV (%)* NRTIs 83% Enfuvirtide 12% *In 60% of 90 patients who received an OBT GSS of the OBT <1 TUPDB204

3 ANRS 139 TRIO Trial – Cape Town 2009 Proportion of patients with HIV RNA < 50 copies/ml at 48 weeks (missing = failure) 3 Wk 24 = 90%Wk 48 = 86% Median CD4 count increase from baseline to week 48 = 108/mm 3 TUPDB204

4 ANRS 139 TRIO Trial – Cape Town 2009 4 Clinical Adverse Events and Laboratory Abnormalities (n=103) Grade 3-4 clinical adverse events 15 (14.6%) possibly related to investigational drugs 4 ( 3.9%) Grade 3-4 laboratory adverse events 20 (19.4%) –Creatinine phosphokinase >5xULN 11 (10.7%) –Gamma-GT >5xULN 4 (3.9%) Adverse events leading to discontinuation 1 (1.0%) = grade 4 skin rash with fever Death 1 (1.0%) = myocardial infarction after aortobifemoral bypass surgery TUPDB204

5 ANRS 139 TRIO Trial – Cape Town 2009 Conclusion In patients with multi-drug resistant virus and few remaining treatment options, at 48 weeks the combination of raltegravir, etravirine and darunavir/r is well tolerated and is associated with a similar rate of virologic suppression than that expected in treatment-naïve patients. 5 TUPDB204

6 ANRS 139 TRIO Trial – Cape Town 2009 6 Acknowledgments The patients for their participation and their commitment during the study and the TRIO Study Group: ANRS JF Delfraissy MJ. Commoy S. Couffin-Cadiergues A. Bouxin-Metro A. Diallo CTU INSERM U897/ISPED G. Chêne C. Fagard C. Jean-Marie A. Beuscart I. Tschöpe C. Colin M. Bertoncello S. Martiren DSMB D. Costagliola J. Caron F. Berdougo D. Rey O. Patey Merck Sharpe & Dohme-Chibret (provided raltegravir) A. Aslan E. Dohin Tibotec, a division of Janssen Cilag (provided etravirine) A. Cheret MB. Hadacek SCIENTIFIC COMMITTEE Y. Yazdanpanah (Chair) G. Chêne D. Descamps V. Dubar C. Jacomet C. Katlama JM. Molina C. Piketty B. Roquebert AM. Taburet CLINICAL CENTERS Saint-Louis, Paris (JM. Molina) Pitié-Salpêtrière, Paris (C. Katlama) Tenon, Paris (G. Pialoux) Saint-Antoine, Paris (PM. Girard) Saint-Louis, Paris (D. Sereni) Tourcoing (Y. Yazdanpanah) Bichat, Paris (P. Yeni) HEGP, Paris (L. Weiss) Nantes (F. Raffi) Paul Brousse, Villejuif (D. Vittecoq) Edouard Herriot, Lyon (F. Jeanblanc) Necker, Paris (JP. Viard) Marseille (I. Poizot-Martin) Lariboisière, Paris (A. Rami) Angers (JM. Chennebault) Garches (P. De Truchis) Saint-Louis, Paris (L. Gerard) Bicêtre (C. Goujard) Nice (J. Durant) Corbeil-Essones (P. Chevojon) Besançon (C. Drobacheff) Antoine Béclère,Clamart (F. Boué) Cochin, Paris (D. Salmon-Ceron) Bordeaux (P. Morlat) Grenoble (P. Leclercq) Saint-Louis, Paris (FJ. Timsit) Saint-Denis(MA. Khuong-Josse) Hôtel-Dieu, Lyon (C. Trepo) Bordeaux (JM. Ragnaud) Belfort (JP. Faller) Nice (E. Rosenthal) Toulouse (L. Cuzin) Créteil (Y. Lévy) Avicenne, Bobigny (M. Bentata) Annecy (J. Gaillat) La Roche/Yon (P. Perré) Rennes (F. Souala) Avignon (G. Pichancourt) Mulhouse (G. Beck-Wirth) Avicenne, Bobigny(S. Abgrall) Pitié-Salpêtrière, Paris (A. Simon) Bordeaux (M. Dupon) Clermont-Ferrand (C. Jacomet) Caen (R. Verdon) Dijon (L. Piroth) Hôtel-Dieu, Paris (A. Compagnucci) Perpignan (H. Aumaitre) Tours (F. Bastides) Pontoise (L. Blum)

7 ANRS 139 TRIO Trial – Cape Town 2009 Back-up slide 7

8 ANRS 139 TRIO Trial – Cape Town 2009 Proportion of patients with HIV-RNA <50 copies/ml at week 48, according to OBT N (%) p-value All patients (n=103) OBT No13/13 (100 ) Yes76/90(84.1) 0.21 Patients with OBT(n=90) Genotypic Sensitivity Score <146/54 (85.2) 11 30/36(83.3) 0.81 8

Download ppt "A Phase II non-comparative multicenter trial Fagard C. 1, Descamps D. 2, Dubar V. 3, Colin C.1,Taburet AM. 4, Roquebert B. 2, Katlama C. 5, Jacomet C."

Similar presentations

Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.

Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.

Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
Switch to RAL-containing regimen - Canadian Study - CHEER - Montreal Study - EASIER - SWITCHMRK - SPIRAL.

Switch to RAL-containing regimen - Canadian Study - CHEER - Montreal Study - EASIER - SWITCHMRK - SPIRAL.
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.

TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction A Case-Control Study Nested within the French Hospital Database on HIV ANRS.

Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction A Case-Control Study Nested within the French Hospital Database on HIV ANRS.
Phase 2 of new ARVs BMS (maturation inhibitor)

Phase 2 of new ARVs BMS (maturation inhibitor)
Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus Potent Antiretroviral Effect.

Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus Potent Antiretroviral Effect.
Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.

Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:

Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE.

A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS REFLATE.
XVIII International AIDS Conference 18-23 July 2010, Vienna, Austria Shionogi-ViiV Healthcare LLC Activity of Next Generation Integrase Inhibitor (INI)

XVIII International AIDS Conference July 2010, Vienna, Austria Shionogi-ViiV Healthcare LLC Activity of Next Generation Integrase Inhibitor (INI)
Comparison of INSTI vs PI  FLAMINGO  GS-236-0103  ACTG A5257  WAVES.

Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257  WAVES.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.

Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
46 th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27 - 30, 2006 San Francisco, California Poster #78 Tenofovir DF + Efavirenz.

46 th Interscience Conference on Antimicrobial Agents and Chemotherapy September , 2006 San Francisco, California Poster #78 Tenofovir DF + Efavirenz.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.

Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.

12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
Maintenance therapy with Trizivir® after 6 months induction with Trizivir® plus either efavirenz or lopinavir/r in naïve patients. Trizefal study J. Mallolas*

Maintenance therapy with Trizivir® after 6 months induction with Trizivir® plus either efavirenz or lopinavir/r in naïve patients. Trizefal study J. Mallolas*

Similar presentations

Ads by Google